CoreValve, Inc. Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving® System for Percutaneous Aortic Valve Replacement (PAVR)
IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that the expanded clinical evaluation of its ReValving® System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace. More than 1,800 patients have now been treated worldwide at nearly 100 centers in 20 countries.